Vanguard Group’s Stoke Therapeutics STOK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$33.4M Buy
2,946,258
+162,056
+6% +$1.84M ﹤0.01% 2311
2025
Q1
$18.5M Buy
2,784,202
+53,004
+2% +$352K ﹤0.01% 2539
2024
Q4
$30.1M Sell
2,731,198
-28,049
-1% -$309K ﹤0.01% 2388
2024
Q3
$33.9M Buy
2,759,247
+71,589
+3% +$880K ﹤0.01% 2348
2024
Q2
$36.3M Buy
2,687,658
+972,104
+57% +$13.1M ﹤0.01% 2273
2024
Q1
$23.2M Buy
1,715,554
+67,052
+4% +$905K ﹤0.01% 2530
2023
Q4
$8.67M Buy
1,648,502
+17,814
+1% +$93.7K ﹤0.01% 3029
2023
Q3
$6.42M Buy
1,630,688
+23,904
+1% +$94.2K ﹤0.01% 3141
2023
Q2
$17.1M Buy
1,606,784
+474,797
+42% +$5.05M ﹤0.01% 2658
2023
Q1
$9.43M Sell
1,131,987
-470,058
-29% -$3.92M ﹤0.01% 2964
2022
Q4
$14.8M Sell
1,602,045
-445,859
-22% -$4.12M ﹤0.01% 2778
2022
Q3
$26.3M Buy
2,047,904
+52,871
+3% +$679K ﹤0.01% 2512
2022
Q2
$26.4M Buy
1,995,033
+55,643
+3% +$735K ﹤0.01% 2514
2022
Q1
$40.8M Buy
1,939,390
+27,208
+1% +$573K ﹤0.01% 2403
2021
Q4
$45.9M Buy
1,912,182
+64,567
+3% +$1.55M ﹤0.01% 2400
2021
Q3
$47M Buy
1,847,615
+108,813
+6% +$2.77M ﹤0.01% 2399
2021
Q2
$58.5M Buy
1,738,802
+77,791
+5% +$2.62M ﹤0.01% 2282
2021
Q1
$64.5M Buy
1,661,011
+54,743
+3% +$2.13M ﹤0.01% 2170
2020
Q4
$99.5M Buy
1,606,268
+300,308
+23% +$18.6M ﹤0.01% 1834
2020
Q3
$43.7M Buy
1,305,960
+27,619
+2% +$925K ﹤0.01% 2084
2020
Q2
$30.5M Buy
1,278,341
+482,351
+61% +$11.5M ﹤0.01% 2230
2020
Q1
$18.2M Buy
795,990
+23,186
+3% +$531K ﹤0.01% 2338
2019
Q4
$21.9M Buy
772,804
+99,220
+15% +$2.81M ﹤0.01% 2495
2019
Q3
$14.5M Buy
673,584
+573,584
+574% +$12.3M ﹤0.01% 2629
2019
Q2
$2.92M Buy
+100,000
New +$2.92M ﹤0.01% 3357